Quick Takeaways
- Squadron Capital Management LLC filed SCHEDULE 13G for Aprea Therapeutics, Inc. Common Stock (APRE).
- Disclosed ownership: 9.9%.
- Date of event: 30 Mar 2026.
Quoteable Key Fact
"Squadron Capital Management LLC disclosed 9.9% ownership in Aprea Therapeutics, Inc. Common Stock (APRE) on 30 Mar 2026."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Squadron Master Fund LP | 9.9% | 1,271,081 | 0 | 1,271,081 | /s/ Matthew Sesterhenn | Partner, Squadron Partners LLC, its General Partner | |
| Squadron Capital Management LLC | 9.9% | 1,271,081 | 0 | 1,271,081 | /s/ Matthew Sesterhenn | Partner | |
| William Blank | 9.9% | 1,271,081 | 0 | 1,271,081 | /s/ William Blank | William Blank | |
| Matthew Sesterhenn | 9.9% | 1,271,081 | 0 | 1,271,081 | /s/ Matthew Sesterhenn | Matthew Sesterhenn |